MoUJul 28, 2026, 04:32 PM
EUDA Health Signs MOU for iPSC-Derived Oncology Cell Therapies
AI Summary
EUDA Health Holdings Ltd announced it has signed a Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd and Shenzhen Innovation Immunotechnology Co., Ltd. This tri-party collaboration aims to develop, manufacture, and commercialize next-generation off-the-shelf oncology cell therapies derived from induced pluripotent stem cells (iPSC) for cancer treatment and wellness. CEO Alfred Lim highlighted the agreement as a significant milestone, aligning with the company's strategy to enhance its commercialization capabilities and increase shareholder value.
Key Highlights
- EUDA Health signed an MOU with GO POSB Organoids and Shenzhen Innovation Immunotechnology.
- The collaboration focuses on next-generation therapies derived from induced pluripotent stem cells (iPSC).
- The parties intend to develop, manufacture, and commercialize off-the-shelf oncology cell therapies.
- The therapies are aimed at cancer treatment applications and wellness.
- CEO Alfred Lim stated the agreement strengthens commercialization and distribution capabilities.
- The company anticipates a robust market for these new therapies and aims to increase shareholder value.
Price Impact
More from EUDA